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The CRISPR/Cas9 technology enables the introduc-
tion of genomic alterations into almost any organism;
however, systems for efficient and inducible gene
modification have been lacking, especially for dele-
tion of essential genes. Here, we describe a drug-
inducible small guide RNA (sgRNA) vector system al-
lowing for ubiquitous and efficient gene deletion in
murine and human cells. This system mediates the
efficient, temporally controlled deletion of MCL-1,
both in vitro and in vivo, in human Burkitt lymphoma
cell lines that require this anti-apoptotic BCL-2 pro-
tein for sustained survival and growth. Unexpectedly,
repeated induction of the same sgRNA generated
similar inactivating mutations in the human Mcl-1
gene due to low mutation variability exerted by the
accompanying non-homologous end-joining (NHEJ)
process. Finally, we were able to generate hemato-
poietic cell compartment-restricted Trp53-knockout
mice, leading to the identification of cancer-promot-
ing mutants of this critical tumor suppressor.
INTRODUCTION
Themanipulation of genes of interest has been vital for decipher-
ing the roles of many signal transducers, regulators of gene
expression, and structural components within a cell or an entire
organism. While ectopic expression of genes in cell lines or pri-
mary cells has been readily achievable for several decades,
the ablation of genes (and their products) has been a consider-
ably harder task, especially in species other than the mouse.
Initial attempts to suppress gene expression included RNA anti-
sense technology (Mizuno et al., 1984), but this has not proven to
be very robust or efficient. The discovery of RNAi improved the
targeting methodology and made it for the first time possible to
knock down the expression of genes in cells of several species
in vitro as well as in vivo (Fire et al., 1998; Sontheimer, 2005).1422 Cell Reports 10, 1422–1432, March 3, 2015 ª2015 The AuthorsHowever, the levels of certain gene products could only be
reduced to a minor extent or not at all; this was particularly the
case for genes that are essential for the sustained growth of cells
(Ottina et al., 2012). A plethora of new genome-editing technolo-
gies, such as zinc-finger nucleases (ZFNs) or transcription acti-
vator-like nucleases (TALENs), have paved the way to overcome
these hurdles. With these technologies, it became possible to
generate targeted gene mutations and knockouts in cell lines
of different species and even whole organisms by directly
mutating the genome rather than by degrading mRNA products.
Although more robust, the complex nature of generating ZNFs
and TALENs makes the routine use of this methodology chal-
lenging. The recently developed CRISPR/Cas9 genome-editing
technology with its high efficiency, ease, speed, and therefore
relatively low expenditure now appears to replace ZNFs and
TALENs to become the method of choice in many laboratories.
Clustered, regularly interspaced, short palindromic repeats
(CRISPRs) and the Cas9 endonuclease have been adapted
from their normal role in bacterial and archaean defense against
phage infections (Barrangou et al., 2007; Wiedenheft et al., 2012)
for the rapid editing of eukaryotic genomes (Cong et al., 2013;
Mali et al., 2013; Pennisi, 2013). The system utilizes the DNA-
cleaving capacity of the Streptococcus pyogenes Cas9 endonu-
clease, which can be directed to specific DNA sequences in
virtually any genome by an engineered small guide RNA (sgRNA)
(Jinek et al., 2012). The resultant sites of DNA cleavage are re-
paired by non-homologous end-joining (NHEJ). This DNA repair
mechanism introduces randommutations into the targeted gene
at high frequency, resulting in its functional inactivation (Jinek
et al., 2012). The Cas9 endonuclease requires sgRNA-mediated
conformational activation to facilitate DNA binding and cleavage
(Jinek et al., 2014).
Despite the advantages offered by CRISPR/Cas9-mediated
gene inactivation, several technical problems impede its use in
many experimental settings. Current tools for Cas9-mediated
genome editing still require subsequent phenotypic or genetic
screening and usually necessitate selection for relatively rare
modified cells. This does not allow for the targeting of essential
genes that may render cells non-viable. Furthermore, with exist-
ing CRISPR/Cas9 methodologies, the overall efficiency of NHEJ
repair within a bulk population of cells is too low to evaluate the
functional consequences of gene inactivation.
To overcome these issues, we sought to improve upon exist-
ing CRISPR/Cas9 techniques to make the system (1) more effi-
cient, (2) applicable to a broader spectrum of cell types, and
(3) temporally controllable. To this end, we engineered a lentiviral
vector platform that allows for efficient transduction of cells and
subsequent inducible expression of sgRNAs with concomitant
constitutive expression of Cas9. We validated the efficiency of
this new platform in human and mouse cell lines in vitro by
knocking out the pro-apoptotic BH3-only protein BIM. In order
to demonstrate the ability of the system to efficiently target
genes that are essential for sustained cell growth, we condition-
ally deleted Mcl-1 in human Burkitt lymphoma (BL) cells, which
are highly dependent on this anti-apoptotic BCL-2 family mem-
ber for their survival (Kelly et al., 2014). Upon induction of the
Mcl-1 sgRNA, these cells were killed at a very high frequency,
and this correlated with the number of InDels (insertions and de-
letions of bases in the DNA) introduced into the Mcl-1 locus by
the NHEJmachinery. Interestingly, when applying a newly devel-
oped next-generation sequencing pipeline, we found that the
frequency and nature of InDels induced by individual sgRNAs
were highly similar to each other, suggesting that the CRISPR/
Cas9-induced NHEJ process is not as random as originally
envisaged. Finally, we used our system to generate hemato-
poietic-cell-restricted Trp53-knockout mice through the intro-
duction of constitutive Cas9 and inducible Trp53 sgRNAs into
hematopoietic stem/progenitor cells (HSPCs) that were then
transplanted into myelo-ablated recipient mice. Interestingly,
we generated not only mutations that caused loss of the
TRP53 protein but also novel mutant TRP53 proteins that could
promote lymphoma development. This shows that our highly
efficient inducible CRISPR/Cas9 platform can be used to identify
novel gene mutations that drive tumorigenesis.
RESULTS
Establishment of an Inducible Lentiviral Guide RNA
Expression System
In order to obtain highly efficient gene-knockout rates in difficult-
to-target mouse and human cell lines and primary cells, we
developed a dual lentiviral vector system consisting of (1) a
constitutive expression vector for the Cas9 endonuclease linked
via the T2A peptide to the mCherry fluorescent marker protein
and (2) a doxycycline (dox)-inducible sgRNA cassette and ubiq-
uitin promoter driven tetracycline (Tet) repressor linked via the
T2A peptide to the GFP protein (Figure 1A). The sgRNA is driven
by the H1 promoter, which permits any start base in the sgRNA
sequence and hence facilitates increased coverage of potential
guide RNA targeting sites within the mammalian genome (Ran-
ganathan et al., 2014). Additionally, the H1 promoter contains a
Tet-operator site, allowing for tight suppression of the promoter
activity in the presence of a codon-optimized Tet repressor,
which can be rapidly and efficiently relieved by the addition of
dox (Herold et al., 2008). We first validated the activity of the viral
vectors in human 293T cells using sgRNAs targeting exon 2 or
exon 3 in the genomic locus of the human pro-apoptotic
BCL-2 family member Bim. Induction of Bim sgRNAs with doxCeled to efficient loss of BIM protein (Figure 1B). DNA sequence
analysis of (non-clonal) cell pools confirmed the modification of
the Bim locus (Figure 1C). We next attempted the knockout of
Bim in the murine factor-dependent cell progenitor-1 (FDC-P1)
myeloid progenitor cell line. To this end, we transduced FDC-
P1 cells that stably express Cas9with dox-inducible sgRNA vec-
tors targeting exon 2 or exon 3 of the genomic locus of the mu-
rineBim gene (isgBim_muEx2 or isgBim_muEx3). Addition of dox
caused a prominent reduction of BIM protein within the whole
population (Figure 1D). We then generated single-cell clones
from the dox-induced FDC-P1 isgBim-knockout populations to
investigate the frequency of loss of the BIM protein and its mo-
lecular basis. Remarkably, 19 out of 20 clones derived from the
parental cell populations transduced with either of the two
sgRNAs targeting Bim showed no residual BIM protein expres-
sion, demonstrating the high efficiency of our lentiviral-based
inducible CRISPR/Cas9 system (Figure 1E). DNA sequence anal-
ysis of the Bim-targeted FDC-P1 clones confirmed the presence
ofmutations in the target sequence (Figure 1F). Remarkably, mu-
tations such as a T insertion leading to a premature stop codon in
the BimmRNA were repeatedly observed in different clones and
also in CRISPR/Cas9-generated BIM-deficient mice using the
same sgRNA (Figure 1F; data not shown).
We also compared the efficiency of a dox-inducible Cas9 lenti-
viral vectorwith our dox-inducible sgRNA system. To this end, we
transduced 293T cells with inducible Cas9 and constitutive
sgBim_huEx2.Additionofdox to the inducibleCas9/sgBim-trans-
ducedcells resulted in nodetectable reductionof theBIMprotein,
while isgBim_huEx2 with constitutive Cas9 showed a strong
reduction in BIM protein levels (Figure S1A). Although both cell
populations were transduced at similar frequencies with the
constitutive and inducible Cas9 expression constructs (Fig-
ure S1B), Cas9 protein levels expressed from the inducible vector
did not reach the same level as in the constitutive expression
setting, even after 72 hr of dox treatment (Figure S1A). This prob-
ably explains the lower targeting efficiency observed with induc-
ible Cas9. To further compare the inducible Cas9 system with
our inducible sgRNA configuration, we established FDC-P1 cell
lines expressing inducible or constitutive Cas9 in combination
with constitutive or inducible sgRNAs, respectively, targeting
exon 2 and exon 3 of the mouse Bim gene. Western blot analysis
confirmed the results obtained in the 293T cells with almost no
lowering of BIM protein using the inducible Cas9 but highly effi-
cient reduction of BIM protein using the inducible sgRNA system
(FigureS1C). In order to quantify andcompare the InDel formation
between the inducible Cas9 and inducible sgRNA system,
we established a next-generation sequencing protocol (Fig-
ure S1D). We isolated genomic DNA from the FDC-P1 cell lines
and amplified 250 bp of the sgRNA-targeted genomic region
using chimeric oligonucleotides (oligos) consisting of gene-spe-
cific and common sequences. The use of the common se-
quences allows for the amplification of the region in a secondary
PCR reaction that incorporates bar-coded oligos as sample
identifiers. The incorporation of differently bar coded forward
and reverse primers and their applicability to any modified
gene reduces the number of oligos needed by up to 80%.
Importantly, while both systems showed minimal InDel formation
in steady state, dox treatment resulted in 60%–80% mutationll Reports 10, 1422–1432, March 3, 2015 ª2015 The Authors 1423
Figure 1. Establishment and Validation of the Inducible Guide RNA Platform
(A) Schematic for doxycycline (dox)-inducible guide RNA lentiviral vectors. Cas9 is constitutively expressed in the cells. Treatment with dox rapidly induces the
sgRNA, which activates Cas9 and directs it to the target genomic sequence.
(B) Targeting of Bim in human 293T cells using human isgBim_huEx2 (huEx2) and human isgBim_huEx3 (huEx3); mouse isgBim_muEx2 (muEx2) was used as a
negative control. Western blotting for human BIM with probing for HSP70 used as a loading control in a whole population of 293T cells transduced with
constitutively expressed Cas9 and dox-inducible sgRNA lentiviral vectors before and after treatment with dox (1 mg/ml).
(C) Conventional Sanger DNA sequencing analysis to confirm the presence of InDel mutations at the target site for the Bim-sgRNA. Representative examples are
shown with reference wild-type sequence in the first line. The sgRNA binding site is shown in green, and InDel mutations are shown in purple.
(D) TargetingofBim in awholepopulationofmouseFDC-P1cellsbeforeandafter treatmentwithdoxusingmouse isgBim_muEx2 (muEx2) andmouse isgBim_muEx3
(muEx3); human isgBim_huEx3 (huEx3) was used as a negative control. Western blotting for mouse BIM with probing for HSP70 used as a loading control.
(E) Efficiency ofBim targeting in 20 single-cell-derived clonal populations ofBim-targeted FDC-P1 cells (numbered A1–A20). Western blotting for mouse BIMwith
probing for HSP70 used as a loading control.
(legend continued on next page)
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rates using the inducible sgRNA as compared to only 5%–10%
for the inducible Cas9 (Figure S1E). This demonstrated that the
inducible sgRNA exerted a more robust effect, and this is likely
due to the ubiquitous and strong activity of the inducible H1 pro-
moter as well as the faster kinetics for transcribing a small RNA
as compared to producing the large Cas9 protein endonuclease
(Ranganathan et al., 2014).
Collectively, these results demonstrate that our new inducible
lentiviral CRISPR/Cas9 platform can be used to efficiently delete
genes in murine and human cell lines.
Analysis of the Consequences of BIM Deletion in Human
BL-Derived Cell Lines
In order to test the applicability of the lentiviral platform in hu-
man hematopoietic cell lines and to assess phenotypic con-
sequences of the targeting of a specific gene, we introduced
isgBim_huEx3 into the human BL-derived cell lines Rael-BL
(Figure 2) and Kem-BL (Figure S2). Due to the inducibility of
our vector system, whole or single-cell clonal populations could
be established by fluorescence-activated cell sorting (FACS)
based on mCherry and eGFP expression (Figure 2A), prior to
sgRNA induction with dox. This strategy optimizes the efficiency
of gene targeting throughout the population of cells after expres-
sion of the sgRNA is induced. Loss of BIM protein in the Rael-BL
cell line (Figure 2B) correlated with resistance to the calcium
ionophore ionomycin (Figure 2C), a cytotoxic insult known to
induce apoptosis in a BIM-dependent manner (Bouillet et al.,
1999). As expected, we detected InDel mutations with high fre-
quency in exon 3 of the Bim locus using the NGS platform (Fig-
ures 2D and S2B).
These results show that the inducible sgRNA lentiviral platform
facilitates efficient deletion of the pro-apoptotic BCL-2 family
member Bim in human hematopoietic lymphoma cell lines and
that this leads to functional inactivation of the BIM protein.
Inducible Deletion of MCL-1 in Human BL-Derived Cell
Lines and Its Functional Consequences
It is conceptually easier to obtain cells bearing mutations in pro-
apoptotic genes (e.g., Bim) than in genes that are essential for
cell survival. Therefore, having established the high efficiency
of our new platform for introducing the desired mutations, we
sought to inactivate theMcl-1 gene in BL cell lines, which require
this anti-apoptotic BCL-2 family member for sustained survival
(Kelly et al., 2014). To confirm the efficacy of the sgRNA targeting
Mcl-1, we first used the Sal-BL cell line that can grow indepen-
dent of MCL-1 due to the expression of the EBV-encoded anti-
apoptotic BCL-2 homolog BHRF-1 (Kelly et al., 2002). MCL-1
protein loss could be readily achieved in this cell line (Figure S3A)
and, as expected, did not cause loss of viability (data not shown).
Next, we turned to Rael-BL cells, which require MCL-1 for sur-
vival (Kelly et al., 2014). Rael-BL cells were stably transduced
with Cas9 and two independent inducible sgRNAs targeting
different regions of the human Mcl-1 gene. Single-cell clones(F) Conventional Sanger DNA sequencing analysis to confirm targeting of themous
mutant mice. DNA sequencing demonstrated a frequently re-occurring T insertio
clones demonstrating homozygousmutated alleles. Comparison ismade toDNA s
displayed reoccurring T insertion. The sgRNA binding site is shown in green, and
Cewere generated by FACS (mCherry/eGFP double-positive cells)
to obtain cell populations that uniformly express Cas9 (reported
by mCherry) and also contain the inducible Mcl-1-targeting
sgRNA (reported by the constitutively expressed eGFP). Induc-
tion of either of the two Mcl-1-targeting sgRNAs by dox effi-
ciently induced apoptosis (up to 75%) in the majority of the
single-cell-cloned lines tested (Figure 3A). As expected, the
loss of MCL-1 protein, as measured by western blotting, corre-
lated with the extent of apoptosis induction observed in these
cells (Figure 3B). Because the sgRNA vector is dox inducible,
we could assess the induction of apoptosis, NHEJ efficiency,
and the pattern of InDel mutations from multiple discrete exper-
iments. Repeated induction of the sgRNAs targetingMcl-1 in the
single-cell-cloned populations resulted in similar reductions in
MCL-1 protein and a similar extent of apoptosis (Figure 3A).
Furthermore, the frequency of InDels generated upon dox induc-
tion in the MCL-1-dependent clonal cell lines correlated strongly
with the extent of cell death; i.e., 60% InDel mutations corre-
sponded to 60%–70% cell killing (Figure 3C). Strikingly, we
detected the generation of similar InDel mutations by the Mcl-
1-specific guide RNAs in different experiments and different
clonal cell populations (Figures 3D, S3B, and S3C). These results
demonstrate that the NHEJ process induced by the CRISPR/
Cas9 system is not as random as envisaged, and it will be inter-
esting to explore the factors that determine this selectivity.
Next, we wanted to test, whether targeting of MCL-1 with our
inducible CRISPR/Cas9 platform would also be usable to
impede tumor growth in vivo. To this end we subcutaneously
injected a variety of the engineered isgMcl-1 BL populations
into immune-deficient non-obese diabetic/severe combined im-
munodeficiency (NOD/SCID) common-g chain knockout (NSG)
mice. We used populations, which upon induction of the Mcl-1
specific guide RNAs in vitro were either killed (responders) or
stayed alive (non-responders). In addition, prior to transplanta-
tion into the NSG mice, these BL lines were transduced with a
luciferase expression vector to allow for monitoring of tumor pro-
gression in vivo using bioluminescent imaging. After 21 days,
successful engraftment was assessed using bioluminescent
imaging and mice bearing tumors were commenced on dox-
containing food to induce the expression of the Mcl-1-specific
sgRNA. Excitingly, 5 days following dox treatment, we observed
dramatic tumor regression (37.5%) or impaired growth (62.5%)
in mice transplanted with responder cells, as compared to
dox-treated mice carrying non-responder cells (Figures 3E
and S3D), which all displayed marked tumor progression. Im-
portantly, these experiments demonstrate that our lentiviral
CRISPR/Cas9 system works highly efficiently in vivo under tem-
poral control and that CRISPR/Cas9-mediated genome editing
may be used as a novel approach to anti-cancer therapy.
In order to further determine (1) the tightness of our systemand
(2) the time at which the first InDels can be detected, we analyzed
InDel formation in the Mcl-1 locus from 0 to 72 hr following dox
application (Figure S3E). Interestingly, InDel formation waseBim locus in clonal FDC-P1 cell lines aswell as CRISPR/Cas9-generatedBim
n. Results are shown for six single-cell-cloned lines (i.e., 12 Bim alleles) with all
equencing results fromCRISPR/Cas9-generatedmutantmice (n = 13) that also
mutations are shown in purple.
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Figure 2. BIM Deletion in Human BL Cell Lines and Next-Generation Sequencing Platform
(A) Representative example of a Rael Burkitt lymphoma (BL) single-cell clonal line obtained by FACS that uniformly expresses Cas9 (reported by mCherry) and
also uniformly contains the inducible sgRNA vector (marked by constitutively expressed eGFP).
(B) Western blotting for BIM (probing for b-actin used as a loading control) demonstrates loss of BIM following dox-mediated induction of the isgBim in a bulk
population of Rael-BL single-cell-derived clonal lines.
(legend continued on next page)
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peaking between 48 and 72 hr, while prior to dox treatment,
almost no InDels could be detected. Accordingly, this correlated
nicely with minimal sgRNA expression before and strong induc-
tion (up to 700-fold increase) after dox treatment peaking be-
tween 12 and 24 hr (Figure S3F). Importantly we observed that
efficient sgRNA induction can be achieved with 10-fold-lower
dox concentrations, and we only saw a drop in this induction
when using 1,000-fold-less dox. To also validate the tightness
of our system in vivo, we compared the engraftment efficiency
and tumor burden in the NSG mice, which were subcutaneously
injected with responder and non-responder cells (Figures S3G
and S3H). Importantly, we observed that in the absence of
dox, the BL clones, which are highly sensitive to induction of
the isgMcl-1, could engraft as readily as the non-responder BL
clones, indicating that the inducible CRISPR/Cas9 system re-
mains tight in vivo.
Collectively, these findings demonstrate the tightness and
high efficiency of our inducible CRISPR/Cas9 genome-editing
system both in vitro and in vivo, and this can be attributed to
the strong inducibility of the sgRNA driven by the H1 promoter.
Therefore, we are able to use this lentiviral platform to even inac-
tivate genes that are essential for the sustained growth of the tar-
geted cells.
Generation of Hematopoietic-Cell-Restricted p53-
Knockout/Mutant Mice
Next, we used our inducible CRISPR/Cas9 lentiviral platform for
the rapid generation of mice lacking a gene/protein specifically
in the hematopoietic compartment. Loss of one allele of Trp53
(Trp53+/) markedly accelerates lymphoma development in
Em-Myc transgenic mice (Schmitt et al., 1999; Michalak et al.,
2009). Therefore, to test our platform in primary cells in vivo,
we transduced fetal-liver-derived HSPCs from Em-Myc mice
with sgRNAs targeting sequences in exon 4 or exon 5 of the
Trp53 gene (jsgTrp53) and transplanted these cells into lethally
irradiated C57BL/6J-Ly5.1 congenic recipient mice that were
then monitored for lymphoma development (Figure 4A). In order
to delete/mutate the Trp53 gene, we treated the transduced
fetal liver cells and the hematopoietic-system-reconstituted
mice with dox. All of these animals rapidly developed pre-B/B
cell lymphoma (median latency of 29 days, with 100% incidence
by 37 days; Figure 4B). In contrast, all mice transplanted with
control sgRNA transduced Em-Myc transgenic HSPCs were still
alive 100 days after reconstitution (p < 0.0001). DNA sequence
analysis of lymphomas revealed that the acceleration in tumor
development was due to targeting of both alleles of Trp53
(Figures S4A and S4B). Accordingly, acceleration of tumor
development was more rapid than that previously reported for
loss of one Trp53 allele (i.e., 100% incidence of lymphomas
by 70 days in Em-Myc;Trp53+/ mice) (Schmitt et al., 1999; Mi-
chalak et al., 2009). Notably, there was an increased proportion
of surface immunoglobulin-M-positive lymphomas (88.2%) as
compared with control Em-Myc mice (30%–40%) (data not(C) Functional validation of Bim deletion. BL cells were treated with ionomycin (5 m
flow cytometer. Data represent mean ± SEM.
(D) Read sequences obtained for human Bim exon 3 sgRNA targeted alleles in the
the top line. DNA sequence changes are highlighted in red.
Ceshown), similar to that previously reported for Em-Myc;Trp53+/
mice (Michalak et al., 2009). The lymphomas that had been
accelerated by the jsgTrp53 sgRNA were resistant to apoptosis
induced by the DNA-damaging agent, etoposide, confirming
that they were functionally Trp53 deficient (Figure 4C). Western
blot analysis demonstrated that some of these lymphomas
completely lacked TRP53 protein (Figure 4D), even after treat-
ment with the Trp53-inducing drug etoposide (Figure 4E). Inter-
estingly, other lymphomas displayed abnormally increased
basal levels of TRP53 protein, as seen in in human as well
as murine cancers carrying mutant Trp53 (Freed-Pastor and
Prives, 2012). The findings from the DNA sequence analysis
and western blot analyses are summarized in Figure 4F. Of
note, in some lymphomas that lack TRP53 protein, no Trp53
gene mutations were detected using the NGS platform. This is
likely due to the occurrence of large deletions that alter the
PCR product or disrupt the primer binding sites. For example,
lymphoma #53 only demonstrated one mutant Trp53 allele;
however, a truncated TRP53 protein was evident by western
blotting (Figure 4D), indicative of a large deletion within the
second Trp53 allele. Interestingly, we again found that many
independent lymphomas contained related InDel mutations
generated by the isgTrp53 (Figures S4A and S4B), similar to
our findings with the isgMcl-1. The generation of stabilized,
overexpressed mutant trp53 proteins in the lymphoma setting
demonstrates that our inducible CRISPR/Cas9 systems offers
an attractive approach to screen for novel tumor-promoting
gain- or loss-of-function mutations in other oncogenes or tu-
mor-suppressor genes, respectively.
DISCUSSION
The use of viral vectors carrying a drug-inducible sgRNA to elicit
Cas9-mediated mutations in genes of interest provides a new
versatility to the use of this exciting technology. We demonstrate
the broad applicability of this systemby knocking out ormutating
genes in cells from different species both in vitro and in vivo.
Temporal control of sgRNA activity allowed for high-efficiency
CRISPR/Cas9-induced NHEJ repair. Importantly, this enabled
the deletion of genes that are essential for sustained cell survival
and growth in vitro and, excitingly, in a human xenograft model
in vivo, showing the potential use of CRISPR/Cas9 in cancer
therapy.
Recently, two dox-inducible Cas9 approaches have been pro-
posed for the conditional deletion of genes. However, one of
these studies never actually used the inducible nature of their
Cas9 expression system to conditionally delete genes (Wang
et al., 2014), and the application of the other was restricted to
one cell type only (Gonza´lez et al., 2014). Importantly, neither
of these studies reported the conditional deletion of genes
that are essential for sustained cell growth. We also tested a
dox-inducible Cas9 lentiviral vector, but we were unable to
achieve the robust effects observed with the ubiquitouslyg/ml) for 72 hr, and cell viability was assessed by exclusion of PI measured in a
Rael-BL cell line after treatment with dox. Wild-type Bim sequence is shown in
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Figure 3. Inducible Deletion of the Essential Gene, Mcl-1, in a Human BL Cell Line with Assessment of Functional Consequences and
Identification of Reoccurring Mutations
(A) Cas9-mediated loss of MCL-1 protein following induction of the Mcl-1 sgRNA by dox leads to apoptosis in a bulk population of MCL-1-dependent human
Burkitt lymphoma (BL) cell lines. Cell viability was assessed by exclusion of PI measured in a flow cytometer. Data represent mean ± SEM and are shown relative
to the negative control (Cas9 negative) *p < 0.05, **p < 0.01, ***p < 0.005.
(B) Western blotting for MCL-1 (probing for HSP70 used as a loading control) shows efficient MCL-1 depletion following dox treatment in the presence of QVD-
OPH (a broad-spectrum caspase inhibitor to prevent apoptosis and consequent protein degradation).
(C) NHEJ efficiency as calculated from percentage of mutant Mcl-1 reads from analysis of MiSeq using the NGS platform as described. Individual values are
shown with mean ± SEM (range across all samples, 13.5% to 96%).
(D) Mutational profile for isgMcl1_huEx1 in the d8 Rael-BL cell line clone whole population after treatment with dox in three independent experiments demon-
strating the presence of dominant and re-occurring mutations.
(legend continued on next page)
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Figure 4. CRISPR/Cas9-Mediated Trp53-Knockout/Mutation in Em-Myc Transgenic Mouse Hematopoietic Stem/Progenitor Cells Acceler-
ates Lymphoma Development In Vivo
(A) Schematic for experimental design. HSPCs were obtained from the fetal liver of E13.5 C57BL/6J-Ly5.2+ mice and maintained in vitro during dual lentiviral
transduction with vectors encoding constitutive Cas9 and the inducible sgRNA. Cells were then injected into lethally irradiated congenic C57BL/6J-Ly5.1+
recipient mice.
(B) Kaplan-Meier survival curve for mice reconstitutedwith Em-MycHSPCs transducedwith Trp53-targeting sgRNA compared tomice reconstitutedwith Em-Myc
HSPCs transducedwith a control sgRNA. The total number of mice (n) in each group is indicated. Median survival for the isgTrp53 cohort is 29 days. ****p < 0.0001
for isgTrp53 mice as compared to control sgRNA mice by log-rank analysis.
(C) Functional Trp53 status was assessed by response of lymphoma cells to etoposide (0.05 mg/ml for 24 hr) treatment in vitro. Cell death was assessed by
exclusion of PI measured in a flow cytometer. Data represent mean ± SEM; ***p < 0.001.
(D) Western blot analysis of each lymphoma for TRP53 protein and p19 with probing for b-actin used as a loading control. 41.2% of Em-Myc isgTrp53 tumors
assessed display abnormally high (stabilized) TRP53 protein, indicative of mutations in Trp53.
(E) Western blot analysis of lymphomas before and after treatment with etoposide (0.5 mg/ml for 24 hr) in the presence of the broad-spectrum caspase inhibitor
QVD-OPH (25 mM) to prevent apoptosis.
(F) Table summary for CRISPR/Cas9-mediated Trp53mutations in lymphomas from selected mice. Mutations leading to in-frame sequence changes are shown
in bold. All in-frame deletions and missense mutations resulting in stabilized overexpressed mutant TRP53 protein are accompanied by non-sense mutations.expressed and strong H1 promoter (Ranganathan et al., 2014)
(Figure S1). Importantly, we found that our system is very
tight, showing almost no leakiness prior to the addition of dox
in vitro and in vivo (Figures S1 and S3E–S3H). This is not only
important for the deletion of essential genes but also critical to
limit potential off-target effects, as Cas9 only becomes func-
tional during the period of dox-induced sgRNA expression.
We have demonstrated the efficacy of our novel system in
both human and mouse cell lines in vitro, in primary murine(E) BLmouse xenograft model to assess lymphoma progression and response to
performed prior (day 0) and 5 days after (day 5) continuous oral administration of
that displayed the greatest impact of dox-inducedMcl-1 deletion on tumor growt
marked tumor progression after dox treatment (non-responders, right panel). Co
Cehematopoietic cells in an in vivo reconstitution model, and,
most excitingly, in a human BL xenograft model in vivo. In
contrast to the previously reported dox-inducible Pol-II systems
(Ottina et al., 2012; Gonza´lez et al., 2014), we achieved high-ef-
ficiency induction as evidenced by robust mutation/knockout
rates and impairment of tumor growth. Recently, an improved
inducible RNAi platform has been developed, which also
allows for efficient knockdown of a diverse set of genes (Fell-
mann et al., 2013). Unlike conventional CRISPR/Cas9-mediatedCRISPR/Cas9-mediated deletion ofMcl-1 in vivo. Bioluminescent imaging was
dox. Shown are the three out of eight mice transplanted with responder clones
h (responders, left panel). All mice bearing non-responder BL clones displayed
lor scale ranges for total photon flux are indicated.
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gene targeting, RNAi is reversible, thereby allowing the re-
expression of a suppressed gene. This might be of interest for
some experimental settings, where consequences of transient
suppression of gene function are desired.
Interestingly, we identified similar mutations induced by the
NHEJ process from individual guide RNAs, even between
different cell populations and experiments, both in vitro and
in vivo. What is the reason for this unexpectedly low level of vari-
ation? One explanation could be that the NHEJ repair mecha-
nism uses short sequence homologies for the joining reaction,
thereby reducing the diversity of mutations (Roth and Wilson,
1986). An alternative explanation could be that the requirement
of the proto-spacer-associated motive (PAM) site for Cas9
recognition and the cleavage site three bases upstream of the
PAM site generate a ‘‘DNA environment’’ that is always repaired
in a similar way. Since this has not been reported before, further
investigations are required to elucidate the precise nature of the
NHEJ DNA repair mechanism following CRISPR/Cas9-mediated
double-strand breaks. This might provide useful information for
designing more powerful sgRNAs to achieve specific knockin
mutations without the requirement of a template DNA for homol-
ogy-directed repair within the targeted genomic locus.
Finally, we have used our novel lentiviral platform to induce
mutations in the tumor-suppressor gene Trp53 in primary
HSPCs, which were then used to reconstitute lethally irradiated
mice. Surprisingly, we obtained different mutants of the TRP53
tumor suppressor that could all accelerate MYC-driven lym-
phoma development. This observation suggests that our
CRISPR/Cas9 system can be adapted for the identification of
novel mutations in oncogenes and tumor-suppressor genes
that can initiate or accelerate tumor development.
EXPERIMENTAL PROCEDURES
Lentiviral Constructs
For the inducible sgRNA constructs, the previously described pFH1tUTG (Her-
old et al., 2008) plasmid was modified to contain the H1-Tet-sgRNA cassette,
which was inserted into Pac I sites upstream of the hUbiquitin promoter. This
sequence contains two bi-directional Bsmb1 sites for subsequent cloning of
different sgRNAsequences. The constitutive sgRNAandCas9 expression vec-
tors were derived from the pFUGW, which has been described previously (Lois
et al., 2002). For the constitutive sgRNA expression, the H1t promoter was in-
serted into the Pac1 site upstream of the hUbiquitin promoter. For the Cas9
expression vector, the eGFP cassette was replaced by the recently described
Cas9 (Cong et al., 2013) linked via the T2A peptide to the mCherry fluorescent
reporter protein. The lentiviral luciferase vector used for transducing the isgMcl-
1 BL cell lines has been recently described (Kelly et al., 2014).
sgRNA Design and Expression Analysis
The MIT CRISPR design software was used for the design of sgRNAs (http://
crispr.mit.edu). To clone individual sgRNAs, 24-bp oligonucleotides contain-
ing the sgRNA sequences were synthesized (Geneworks). They included a
4-bp overhang for the forward (TCCC) and complementary reverse (AAAC)
oligos to enable cloning into the Bsmb-I site of the lentiviral construct. sgRNA
sequences are as follows: Trp53 exon 4: 50-GGCAACTATGGCTTCCACCT-30;
Trp53 exon 5: 50-GAGCGCTGCTCCGATGGTGA; mBim exon 2: 50-GACA
ATTGCAGCCTGCTGAG; mBim exon 3: 50-GCACAGGAGCTGCGGCGGAT;
hBim exon 2: 50-GCCTCCCCAGCTCAGACCTG; hBim exon 3: 50-GCCCAA
GAGTTGCGGCGTAT; hMcl1 exon 1.1: 50-GGAGCTGGACGGGTACGAGC;
hMcl1 exon 1.2: 50-GGGAGGGCGACTTTTGGCTA.
To analyze the sgRNA expression, RNAwas first extractedwith RNeasymini
columns (QIAGEN 74104) and 1 mg of extracted RNA was used for reverse1430 Cell Reports 10, 1422–1432, March 3, 2015 ª2015 The Authorstranscription and first-strand cDNA synthesis. 2 mM of primer (50-AAAAG
CACCGACTCGGTGCC-30) specific for the common 30 scaffold sequence
of sgRNAs was added to each reverse transcription reaction along with dinu-
cleotide triphosphates, RNase inhibitor, and SuperScript III reverse transcrip-
tase. Reactions were incubated for 1 hr at 50C. For quantification of sgRNA
cDNA sequences, TaqMan qPCR was conducted using forward primer (50-
CGGTAATCGGACTCAACCTCTA-30), reverse primer (50-CGCTTCCGCCAAT
CACC 30), and FAM-labeled TaqMan probe (50 TTTGGCTACGGAGAAGGA
GGCC 30).
Tissue Culture
The mouse FDC-P1 cell line was grown in high-glucose DMEM supplemented
with 10% fetal calf serum (FCS) (Gibco), 50 mM mercaptoethanol (Sigma-Al-
drich), 100 mM asparagine (Sigma-Aldrich), 100 U/ml penicillin, 100 mg/ml
streptomycin (Gibco), and IL-3 (10 ng/ml) at 37C in 10% CO2. HEK293T cells
were maintained in DMEMwith 10% FCS. Prior to transfection, HEK293T cells
were cultured in DME Glutamax (Gibco) supplemented with 10% FCS and
25 mM HEPES. Rael-BL, Kem-BL, and Sal-BL human-BL-derived cell lines
have been described previously (Kelly et al., 2002). These cell lines were
cultured in RPMI-1640 supplemented with 10% FCS, 1mM glutamine (Gibco),
1 mM sodium pyruvate (Gibco) and 50 mM thioglycerol (Sigma-Aldrich), main-
tained in 5% CO2.
Virus Production and Transduction of Cell Lines
Lentiviral particles were produced by transient transfection of 293T cells grown
in 10-cm Petri dishes with 10 mg of vector DNA along with the packaging con-
structs pMDL (5 mg), pRSV-rev (2.5 mg), and either pENV (5 mg) (for fetal liver cell
infections) or pVSV-G (3 mg) (for cell line infections) using standard calcium
phosphate precipitation as previously described (Herold et al., 2008). Virus-
containing supernatants were collected at 48–72 hr after transfection and
passed through a 0.45-mm filter. For infection of 293T cells, cells were plated
at 13 104 cells per 12-well plate in 1-ml viral supernatant plus 1ml DMEMwith
10% FCS; cells were left for 72 hr. For mouse FDC-P1 and human BL cell lines,
aliquots of 1.0 3 105 cells were suspended in 8 ml of virus-containing super-
natant with 10 ng/ml polybrene, incubated for 30 min at 37C, and then centri-
fuged at 2,200 rpm for 2.5 hr at 32C.
Flow Cytometric Analysis and Cell Sorting
Assessment of eGFP and mCherry expression in cell lines as well as
immunophenotyping of Em-Myc lymphomas was performed using an LSR
IIW or FACSCalibur flow cytometer (Becton Dickinson). Immunophenotyping
of Em-Myc lymphomas was performed on single-cell suspensions that
were stained with surface-marker-specific antibodies. The following fluoro-
chrome-conjugated antibodies were utilized: CD19 (clone ID3), B220 (RA3-
6B2), IgM (clone 5.1), IgD (clone 11-26C), CD4 (clone H129), CD8 (clone
YTS.169), Mac-1 (cloneM1/70) and Gr-1 (clone RB6-8C5). To confirm the lym-
phomaswere of donor hematopoietic cell derived origin, staining for Ly5.2 was
also performed. Antibodies were produced in our laboratory and conjugated to
R-phycoerythrin (R-PE) or allophycocyanin according to the manufacturer’s
instructions. Virally transduced cell lines were sorted using an Aria W flow
cytometer by two methods: (1) all cells positive for eGFP and mCherry were
sorted to produce a bulk population of double-positive cells (referred to as a
whole population), or (2) dual-positive eGFP and mCherry cells were sorted
on a single-cell basis into a single well of a 96-well plate to propagate a homog-
enous cell population (referred to as single-cell clones).
Dox Treatment
For treatment of cell lines to induce expression of the sgRNA, dox hyclate
(Sigma-Aldrich D9891) was dissolved in sterile water at a stock concentration
of 10 mg/ml and added to tissue culture medium for a final concentration of
1 mg/ml. For in vivo experiments, standard rodent diet was supplemented
with dox 600 mg/kg body weight (Specialty Feeds, SF08-026).
Drug Treatments and Functional Assays
The viability of cultured cells was determined by exclusion of propidium iodide
(PI) as assessed by flow cytometry. PI-negative cells were considered viable,
and this was expressed as a percentage of the viability of a matched untreated
control cell population. Single-cell clones were obtained for Rael-BL and Kem-
BL cell lines transduced with both isgBim and Cas9. Tissue culture medium
was supplemented with 5 mg/ml ionomycin, and cell viability was assessed
by exclusion of PI after 72 hr. Single-cell clones were obtained for Rael-BL
clones transduced with both isgMcl-1 and Cas9. At commencement of func-
tional assays, the tissue culture medium was supplemented with 1 mg/ml
dox to induce the isgMcl-1 in the entire cell population. Cell viability was as-
sessed after 72 hr, at which time point samples for analyses of genomic
DNA and protein (western blotting) were also collected. To assess the
TRP53 functional status of the isgTrp53 Em-Myc lymphomas, cell lines derived
from these tumors were treated in vitro with etoposide 0.05 mg/ml and cell
viability assessed by exclusion of PI after 24 hr.
Western Blot Analysis
Total protein extracts were prepared from cell lines and primary tumor samples
by lysis in RIPA buffer supplemented with protease inhibitors (complete
protease inhibitor cocktail, Roche). Protein extracts were quantitated using
the Bradford assay (Bio-Rad). Total protein extracts were separated by
SDS-PAGE and transferred onto nitrocellulose membranes. Membranes
were blocked using 5% milk in PBS with 0.1% Tween 20 prior to incubation
with the primary antibody. Polyclonal antibodies were used to detect mouse
MCL-1 (Rockland antibodies and assays), and BIM (Enzo Life Sciences,
ADI-AAP-330-E); monoclonal antibodies were used to detect mouse TRP53
(CM5, Novocastra), p19/ARF (clone 5.C3.1, Rockland Antibodies and Assays),
b-actin (clone AC74, Sigma-Aldrich; loading control), HSP70 (clone N6;
gift from Dr. R. Anderson, Peter MacCallum Cancer Research Institute,
Melbourne, Australia; loading control), human MCL-1 (clone 19C4-15) and
Cas9 (Diagenode, #C15200203). Etoposide treatment of Em-Myc lymphoma
cells was performed in vitro using etoposide (0.5 mg/ml) in the presence of
the broad-spectrum caspase inhibitor QVD-OPH (MP Biomedicals, ca-
t#OPH109) to prevent cell death and associated protein degradation. Cells
were plated at 5 3 105 cells per 24-well plate, and protein extracts were ob-
tained after 24 hr.
Animal Experiments
Experiments withmicewere conducted according to the guidelines of theWal-
ter and Eliza Hall Institute animal ethics committee. Em-Myc transgenic mice
(C57BL/6J) have been described previously (Adams et al., 1985). CRISPR/
Cas9 Bim mutant mice (C57Bl/6J) were generated as described before
(Wang et al., 2013). For the human xenograft experiments, 1 3 106 lucif-
erase-transduced BL cell lines were injected into NSG mice. After 21 days,
the tumor burden was visualized using bioluminescent imaging. Prior to imag-
ing, mice were administered with 200 ml of 15-mg/ml D-luciferin potassium salt
(Caliper Life Sciences) in PBS by intraperitoneal (i.p.) injection. Mice were then
anaesthetized using isoflurane inhalant and imaged using the IVIS live-imaging
system (Perkin Elmer) to detect luciferase bioluminescence exactly 15 min af-
ter administration of the luciferin substrate. The tumor burden was quantified
bymeasuring the total photon flux per second emitted from a region of interest
drawn around the whole mouse. When the lymphoma burden was sufficiently
high (photon flux per second of >1 3 107), successfully engrafted mice from
each cohort were administered dox-containing food for 5 days and regression
or progression was assessed by repeat bioluminescence imaging. For he-
matopoietic reconstitutions, fresh embryonic day 13.5 (E13.5) fetal liver cells
(a rich source of HSPCs) were obtained from C57BL/6J-Ly5.2+ mice and
placed into alpha-minimum essential medium (a-MEM) with glutamax (Gibco)
supplemented with 10% FCS, 1 mM L-glutamine, 1 mM sodium pyruvate,
100 mg/ml streptomycin, 100 U/ml penicillin, 10 mMHEPES, 50 mM b-mercap-
toethanol containing the cytokines IL-6 (10 ng/ml), stem cell factor (100 ng/ml),
thrombopoietin (50 ng/ml) and FLT-3 ligand (10 ng/ml). Fetal liver cells were
maintained in culture for approximately 72 hr during lentiviral infection. Dual
lentiviral infection was performed with (1) constitutive Cas9-mCherry and (2)
dox-inducible sgRNA-eGFP lentivirus. Viral supernatants were collected as
described above, and 10 ng/ml polybrene was added. Viral supernatants
were combined at a ratio of three parts Cas9 virus to two parts sgRNA virus
to allow simultaneous infection. Infections were performed in a 6-well non-tis-
sue-culture-treated plate previously coated overnight with retronectin solution
(32 mg/ml in PBS) at 4C followed by coating with 2% albumin solution fromCebovine serum (Sigma-Aldrich A1595) in PBS at 37C for 30 min prior to coating
with viral particles. Viral particles were centrifuged onto the retronectin-coated
plates at 3,500 rpm for 1 hr. Fetal liver cells were then added to each well and
incubated for 24 hr. A second round of lentiviral infection was performed on
day 2, at which time medium was also supplemented with 1 mg/ml dox. Trans-
duced cells were collected, washed in PBS, and injected into lethally irradiated
(23 5.5Gy, 4 hr apart) C57BL/6J-Ly5.1+mice. Recipient miceweremaintained
on dox-containing food during the period of reconstitution.
Statistical Analysis
GraphPad Prism software was used for generating Kaplan-Meier animal sur-
vival curves and statistical analysis comparing survival curves by log-rank
test. GraphPad software was also used in the analysis of death assays with
etoposide-, ionomycin-, and dox-induced Mcl-1 deletion. Paired two-tailed
t tests were performed to compare samples.
Sanger Sequencing of sgRNA Target Sites
Genomic DNAwas isolated from cells using the DNeasy kit (QIAGEN). PCR us-
ing AccuPrime (Invitrogen) was performed using primers flanking the target
sites for the human and mouse Bim sgRNAs (primer numbers: 369 370
[mouse]). PCR products were blunt-end ligated into plasmids using the Zero
Blunt TOPO PCR Cloning Kit (Invitrogen). Plasmids were transformed by elec-
troporation into DH10a-competent bacteria (Invitrogen). Single bacterial col-
onies were grown in Luria broth supplemented with kanamycin, and plasmid
DNA was purified by standard mini-prep protocol. DNA sequencing was per-
formed by conventional Sanger sequencing (Australian Genome Research Fa-
cility). For FDC-P1 cell lines, genomic DNA was obtained from single-cell
clones. For 293T cells, genomic DNA was obtained from whole populations
of cells.
Targeted PCR of Sites of Cas9-Induced InDels
Preparation of genomic DNA was performed by placing cells directly into
Direct PCR lysis buffer (Viagen) with proteinase K (Sigma-Aldrich P4850) and
incubated at 56C for 4 hr followed by heat inactivation at 85C for 40 min.
Unique primers were designed to span the expected InDel positions in the
genomic DNA, such that approximately 120 bp of DNA sequence 50 and 30
of predicted Cas9-mediated double-strand breaks would be amplified during
the first PCR reaction. The amplicon size range generated was 200-300 bp
so that these fragments could be sequenced using the Illumina MiSeq plat-
form. The unique primers were synthesized to include a 22 and 21 base
overhang at the 50 end of the forward and reverse primers, respectively
(OH1: 50-GTGACCTATGAACTCAGGAGTC-30; OH2: 50-CTGAGACTTGCAC
ATCGCAGC-30). The PCR cycling conditions were as follows (PCR 1: 95C
2 min [95C 15 s, 60C 15 s, 72C 30 s] 3 18, 72C 7 min, 4C hold step).
PCR ampliconswere individually purified using 1.03Ampure Beads (Beckman
Coulter). Amplicon size distribution was ascertained using the Agilent Tapes-
tation D1000 protocol.
Secondary Amplification using Overhang Sequences
In order to maximize sample sequencing on the Illumina MiSeq platform, indi-
vidual amplicon identification was devised using eight base index sequences
derived from the Illumina Nextera design. This approach ensured that the
required sequences (flow-cell binding and sequencing primers) for Illumina
sequencing technology were incorporated into PCR amplicons generated dur-
ing the primary amplification step, during the following secondary overhang
amplification step. Eight forward index primers and 12 reverse index primers





NNNNNNNN is where individual indexes are placed in the oligo design.)
The PCR cycling conditions were as follows (PCR 2: 95C for 2 min [95C for
15 s, 60C for 15 s, 72C for 30 s] 3 24, 72C for 7 min, 4C hold step). Ampli-
con size distribution was ascertained using the Agilent Tapestation D1000
protocol. The 96 reactions from the entire plate were pooled and the PCR am-
plicons purified using 1.03 Ampure Beads (Beckman Coulter).ll Reports 10, 1422–1432, March 3, 2015 ª2015 The Authors 1431
Illumina MiSeq Sequencing
Each dual indexed library plate pool was quantified using the Agilent Tapesta-
tion and the Qubit RNA assay kit for Qubit 2.0 Fluorometer (Life Technologies).
The indexed pool was diluted to 12 pM for sequencing on a MiSeq instrument
(Illumina) according to the manufacturer’s instructions. The 300-cycle kit was
used for amplicon sizes of less than 280 bp, and these amplicons were
sequenced as single reads (281 cycles) followed by a 44-cycle second index
read. Amplicons that were larger than 280 bp were sequenced using the
600-cycle kit, and both reads 1 and 2 were sequenced for 311 cycles.
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